ECDC and the WHO Regional Office for Europe (WHO/Europe) recently concluded a crucial joint meeting focused on enhancing tuberculosis (TB) surveillance and monitoring across the WHO European Region.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
The European Respiratory Diseases Forecasting Hub (RespiCast) is open for weekly submission of several respiratory disease indicators such as influenza-like-illness, acute respiratory infection and COVID-19.
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.
Seasonal influenza is a vaccine-preventable disease and annual influenza vaccination is the most effective way to prevent influenza. ECDC continues to emphasise that all Europeans who are recommended to have the influenza vaccine should get vaccinated.